Clinical Trials Browser

Phase 3 × Colorectal Neoplasms × sintilimab × Clear all

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer